EA201100626A1 - Лечение рака с помощью ионизирующего облучения и иммуноцитокинов - Google Patents

Лечение рака с помощью ионизирующего облучения и иммуноцитокинов

Info

Publication number
EA201100626A1
EA201100626A1 EA201100626A EA201100626A EA201100626A1 EA 201100626 A1 EA201100626 A1 EA 201100626A1 EA 201100626 A EA201100626 A EA 201100626A EA 201100626 A EA201100626 A EA 201100626A EA 201100626 A1 EA201100626 A1 EA 201100626A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunocytokins
cancer
help
treatment
ionizing radiation
Prior art date
Application number
EA201100626A
Other languages
English (en)
Russian (ru)
Inventor
Томас Уикхем
Ульрике Гнад-Фогт
Штефан Г. Клинц
Силвиа А. Холден
Карл Йозеф Каллен
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201100626A1 publication Critical patent/EA201100626A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/208IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201100626A 2008-10-21 2009-10-21 Лечение рака с помощью ионизирующего облучения и иммуноцитокинов EA201100626A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10714608P 2008-10-21 2008-10-21
PCT/EP2009/007533 WO2010046097A1 (en) 2008-10-21 2009-10-21 Cancer treatments with radiation and immunocytokines

Publications (1)

Publication Number Publication Date
EA201100626A1 true EA201100626A1 (ru) 2011-12-30

Family

ID=41510762

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100626A EA201100626A1 (ru) 2008-10-21 2009-10-21 Лечение рака с помощью ионизирующего облучения и иммуноцитокинов

Country Status (12)

Country Link
US (1) US20100330029A1 (enExample)
EP (1) EP2337579A1 (enExample)
JP (1) JP2012506394A (enExample)
KR (1) KR20110086101A (enExample)
CN (1) CN102196815A (enExample)
AU (1) AU2009306711A1 (enExample)
BR (1) BRPI0919857A2 (enExample)
CA (1) CA2741130A1 (enExample)
EA (1) EA201100626A1 (enExample)
MX (1) MX2011004193A (enExample)
WO (1) WO2010046097A1 (enExample)
ZA (1) ZA201103726B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3107573T (pt) * 2014-02-19 2019-01-10 Merck Patent Gmbh Imunoterapia com il-12 visada ao cancro
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
US9861833B1 (en) * 2017-03-30 2018-01-09 Norman H. Anderson Methods of treating melanoma
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. MADCAM TARGETED IMMUNOTLERANCE
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN112768029B (zh) * 2020-12-27 2023-10-13 上海市东方医院(同济大学附属东方医院) 一种基于单细胞测序的组合用药推荐设备、方法及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2457701A (en) * 1999-12-28 2001-07-09 Brown University Research Foundation Methods and products for tumor immunotherapy using cytokines
ATE368475T1 (de) * 2000-06-29 2007-08-15 Emd Lexigen Res Ct Corp Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
RU2007130552A (ru) * 2005-01-10 2009-02-20 Рисерч Дивелопмент Фаундейшн (US) Рекомбинантные молекулы направленного действия для лечения рака
PT1966238E (pt) * 2005-12-30 2012-07-31 Merck Patent Gmbh Uso de hsp70 como um regulador de atividade enzimática

Also Published As

Publication number Publication date
BRPI0919857A2 (pt) 2015-12-15
AU2009306711A1 (en) 2010-04-29
WO2010046097A1 (en) 2010-04-29
ZA201103726B (en) 2012-01-25
JP2012506394A (ja) 2012-03-15
KR20110086101A (ko) 2011-07-27
MX2011004193A (es) 2011-05-24
CN102196815A (zh) 2011-09-21
US20100330029A1 (en) 2010-12-30
CA2741130A1 (en) 2010-04-29
EP2337579A1 (en) 2011-06-29

Similar Documents

Publication Publication Date Title
EA201100626A1 (ru) Лечение рака с помощью ионизирующего облучения и иммуноцитокинов
CY1123258T1 (el) Μεθοδος θεραπειας για τον καρκινο
MX2020009773A (es) Terapia de combinacion.
CY1115782T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
SG10201902664RA (en) Combination therapy for treating cancer
MXPA05011656A (es) Combinaciones para el tratamiento de enfermedades que implican proliferacion, migracion o apoptosis celulares de celulas de mieloma, o angiogenesis.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
WO2011146777A3 (en) Device and method for providing a synergistic combination of phototherapy and a non-light energy modality to the brain
PH12015502260B1 (en) C. novyi for the treatment of solid tumors in humans
MX2020001727A (es) Terapia de combinacion.
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
EA201001853A1 (ru) Фармацевтическая комбинация
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
PH12021551276A1 (en) Combination therapy for the treatment of cancer
MX2025008270A (es) Uso prolongado de docetaxel en el tratamiento del cáncer.
EA202192964A1 (ru) Комбинированная терапия
MX2021001764A (es) Terapia de combinacion.
MX2021001288A (es) Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer.
BR112022001796A2 (pt) Tratamento focal do câncer de próstata
WO2018231799A8 (en) Methods of treating brain tumors using combination therapy
MX393477B (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.
ATE442188T1 (de) Bestrahlungseinrichtung
TW200724158A (en) Combination therapy in the treatment of cancer
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
BR112022001814A2 (pt) Métodos de tratamento de câncer multifocal